Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market
This article was originally published in The Rose Sheet
Executive Summary
After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.
You may also be interested in...
Perrigo Feeds OTC Brand Play With Prevacid As GSK Thins Consumer Lineup
Already providing generic equivalents, Perrigo buys national brand from GSK as it acts on commitment to move into brand product sales. Plans to expand OTC Prevacid line, likely with an orally disintegrating tablet, and to grow entire US OTC gastrointestinal category.
Oral Care Drives OTC Sales As Glaxo Buffs Its Consumer Health Shine
GlaxoSmithKline consumer health sales grow 3% at constant exchange rates during the second quarter driven by Sensodyne oral care and medicated skin care products. CEO Emma Walmsley dismisses rumors of divesting the business, saying firm continues to see “very good potential for growth and performance” of consumer health.
Oral Care Drives OTC Sales As Glaxo Buffs Its Consumer Health Shine
GlaxoSmithKline consumer health sales grow 3% at constant exchange rates during the second quarter driven by Sensodyne oral care and medicated skin care products. CEO Emma Walmsley dismisses rumors of divesting the business, saying firm continues to see “very good potential for growth and performance” of consumer health.